Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab).

Please see full Prescribing Information available at www.bms.com.

The company will provide additional details on the approval in a press release to follow.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.